Gout
Conditions
Brief summary
This study will explore the safety, tolerability, and serum uric acid lowering effect of RDEA3170 in healthy Japanese males to allow comparison with the Western population.
Detailed description
While clinical studies of RDEA3170 to date have been limited to a Western population, it is recognized that both intrinsic and extrinsic factors may impact the PK, PD, safety, and dose response in different ethnic populations. The purpose of this study is to explore the safety, tolerability, pharmacokinetic (PK), and pharmacodynamic (PD) of single and multiple doses of RDEA3170 in healthy Japanese males, and to allow comparison of these parameters with the Western population.
Interventions
DRUGRDEA3170 and Placebo
Sponsors
Ardea Biosciences, Inc.
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Subject)
Eligibility
Sex/Gender
MALE
Age
20 Years to 55 Years
Healthy volunteers
Yes
Inclusion criteria
* Able to understand the study procedures and the risks involved, and willing to provide written informed consent before the first study related activity. * Healthy adult male subject born in Japan. * Subject has parents and grandparents who are Japanese. * Subject is in possession of a valid Japanese passport. * All laboratory parameters should be within normal limits or considered not clinically significant by the investigator. * Screening serum urate level ≥ 4.5 mg/dL. * Subject is free of any clinically significant disease that requires a physician's care and/or would interfere with study evaluations or procedures. * Subject has a normal or clinically acceptable physical examination. * Subject has no clinically relevant abnormalities in blood pressure, heart rate, and body temperature, per the Investigator's judgment.
Exclusion criteria
* Positive serology to human immunodeficiency virus (HIV-1 or HIV-2). * Positive test for active hepatitis B or hepatitis C infection. * History or suspicion of kidney stones. * Undergone major surgery within 3 months prior to Day 1. * Exposed to an investigational drug (or a medical device) within 30 days or 5 half-lives of the investigational drug (whichever is longer) prior to Day 1 or is currently participating in another study of an investigational drug (or medical device). * Prior exposure to RDEA3170.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Incidence of Adverse Events and Changes in Laboratory, Electrocardiogram, and Vital Signs Parameters | 5 to 6 weeks | — |
| PK profile of RDEA3170 from plasma and urine | Day 1 through 15 | Profile in terms of AUC, Tmax, Cmax, and t1/2 AUC: area under the plasma concentration versus time curve; Tmax: time to maximum plasma concentration; Cmax: maximum plasma drug concentration; t1/2: apparent terminal half-life |
| PD profile of RDEA3170 from serum and urine | Day 1 through 15 | Profile in terms of sUA concentration; CLr; urine uric acid excretion amount; fractional excretion of uric acid sUA: serume urate; CLr: renal clearance |
Countries
United States
Outcome results
None listed